BCRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BioCryst Pharmaceuticals Inc (BCRX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are positive long-term growth projections and analyst ratings, the lack of recent trading signals, insider selling, and weak financial performance in the latest quarter suggest waiting for a better entry point.
The MACD is slightly positive but contracting, RSI is neutral at 51.423, and moving averages are converging, indicating no clear trend. Key support is at 8.087, and resistance is at 8.844. The stock is trading below the pivot level of 8.465, showing mild bearish pressure.
Analyst ratings are positive, with price targets ranging from $17 to $32, reflecting long-term growth potential. The acquisition of Astria Therapeutics and the expected peak sales of Orladeyo and navenibart are seen as strategic moves for future revenue growth.
Insider selling has increased significantly by 1842.59% over the last month, which could indicate a lack of confidence from insiders. Additionally, the latest financial performance shows a significant drop in net income (-1017.50% YoY) and EPS (-961.54% YoY), despite revenue growth.
In Q4 2025, revenue increased by 209.09% YoY to $406.56M, but net income dropped by -1017.50% YoY to $245.85M, and EPS fell by -961.54% YoY to 1.12. Gross margin improved slightly to 97.66%. The financials show strong revenue growth but significant profitability challenges.
Analysts are optimistic about the stock, with multiple 'Outperform' and 'Buy' ratings. Price targets range from $17 to $32, driven by growth expectations for Orladeyo and navenibart, as well as strategic acquisitions like Astria Therapeutics.
